| Identification | Back Directory | [Name]
N-[2-Methyl-2-(2-phenyloxazol-4-yl)propyl]-3-[5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl]benzaMide | [CAS]
1314891-22-9 | [Synonyms]
TFMO 2
CS-2651
TMP 195
TMP195; TMP-195
TMP 195 - TFMO 2
TMP-195;TMP195;TMP 195
N-[2-Methyl-2-(2-phenyloxazol-4-yl)propyl]-3-[5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl]benzaMide | [Molecular Formula]
C23H19F3N4O3 | [MDL Number]
MFCD26522024 | [MOL File]
1314891-22-9.mol | [Molecular Weight]
456.42 |
| Chemical Properties | Back Directory | [density ]
1.303±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 10 mg/ml; DMSO: 10 mg/ml; Ethanol: 10 mg/ml; PBS (pH 7.2): 0.2 mg/ml | [form ]
A crystalline solid | [pka]
13.05±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
TMP195 (TFMO 2) is a selective class IIa HDAC inhibitor with IC50 of 300 nM in cell-based assays. | [in vitro]
TMP195 has low potency in recombinant class I and class IIb HDAC assays, and is able to completely inhibit class IIa HDAC activity without inhibiting other HDACs. In the supernatant of monocyte-derived macrophage differentiation medium, it prevented the accumulation of CCL2 protein; compared with the control group, it could significantly increase the level of CCL1 protein secreted by monocytes. | [target]
| Target | Value | HDAC9
(Cell-free assay) | 15 nM(Ki) | HDAC7
(Cell-free assay) | 26 nM(Ki) | HDAC4
(Cell-free assay) | 59 nM(Ki) | HDAC5
(Cell-free assay) | 60 nM(Ki) |
| [storage]
Store at -20°C |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|